Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Vaccines may make the body build an immune response to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.

Key facts

Study ID

NCT00004052

Run by

Memorial Sloan Kettering Cancer Center

People needed

24

Starts

1999-03-01

Expected to finish

2005-08-01

Last updated by the study team

2013-06-25

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.